Skip to main content

Table 1 Summary of the identified studies

From: Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis

Study

Study design

Country

Enrollment

Inclusion criteria*

MR-MAC-PD Pts /Total Pts, n / n (%)

Age, year

Female, n (%)

BMI, kg/m2

FC type, n (%)

Never smoker, n (%)

M. intracellulare / M. avium, n (%) / n (%)

Tanaka 1999 [13]

Prospective observational

Japan

Nov 1992 – Nov 1997

>  32

6 / 46 (13)

NA

4 (67)

NR

NA

NA

NA

Griffith 2006 [5]

Retrospective observational

United States

1991–2005

≥ 32

51 / 51 (100)

64.7 ± 13.6

28 (55)

NR

27 (53)

18 (35)

41 (77) / 12 (23)

Moon 2016 [6]

Retrospective observational

South Korea

Jan 2002 – Dec 2014

≥ 32

34 / 34 (100)

65 (61–70)

11 (32)

19.7 (17.3–21.2)

19 (56)

20 (59)

21 (62) / 13 (38)

Morimoto 2016 [7]

Retrospective observational

Japan

Sep 2005 – Jul 2014

>  32

90 / 90 (100)

68 (60–74)

67 (74)

17.4 (15.7–19.6)

27 (30)

67 (74)

15 (17) / 50 (56)

Kadota 2016 [8]

Retrospective observational

Japan

Jan 2009 – Jun 2013

≥ 32

33 / 33 (100)

67 ± 9

31 (94)

17.2 ± 5.0

25 (76)

30 (91)

NR

Yagi 2017 [14]

Retrospective observational

Japan

Jan 2014 – May 2016

≥ 32

9 / 26 (35)

NA

8 (89)

NA

4 (44)

NA

0 (0) / 9 (100)

Aznar 2018 [15]

Retrospective observational

Canada

Jul 2003 – Dec 2016

NR

8 / 54 (15)

surgery 67.5 (64–69.5) non-surgery 66 (57.5–77.5)

8 (100)

NA

0 (0)

NR

NA

Griffith 2018 [16]

Prospective randomized

Global

May 2015 – Jan 2017

≥ 32

73 / 336 (22)

NA

NA

NA

NR

NA

NR

Asakura 2019 [17]

Retrospective observational

Japan

Jan 2010 – Jul 2017

≥ 32

15 / 31 (48)

NA

12 (80)

≤18.5: 9 (60%) > 18.5: 6 (40%)

NA

NA

NA

  1. Note: Data are presented as mean ± standard deviation or median (interquartile range) unless otherwise indicated
  2. *Minimal inhibitory concentration of clarithromycin, μg/mL
  3. †The study was conducted at 127 clinical centers in 18 countries in North America, Asia-Pacific region, and Europe
  4. Abbreviations: MR-MAC-PD macrolide-resistant M. avium complex pulmonary disease, BMI body mass index, FC fibrocavitary, Pts patients, NR not reported in the article, NA specific data for MR-MAC-PD patients are not available